Department of Surgery Oncology and Gastroenterology, University of Padova, Italy.
Istituto Oncologico Veneto, IOV-IRCCS, Padova, Italy.
J Natl Cancer Inst. 2017 Mar 1;109(3):1-9. doi: 10.1093/jnci/djw230.
Vitamin B6 is involved in many biochemical reactions and might play a role in carcinogenesis. We summarized the evidence linking vitamin B6 to cancer risk.
We conducted a systematic review of both observational and intervention studies investigating the relationship between vitamin B6 intake or blood levels of its bioactive form pyridoxal-5'-phosphate (PLP) and the risk of any type of cancer. Random-effects meta-analysis was used to calculate pooled relative risks (RRs) and their 95% confidence intervals (CIs) across studies for high vs low categories of vitamin intake or PLP levels. We also performed a random-effects dose-response meta-analysis.
We identified 121 observational studies (participants, n = 1 924 506; cases, n = 96 , 436) and nine randomized controlled trials (RCTs; participants, n = 34 911; cases, n = 2539) considering 19 tumor sites. High intake of dietary (food only) vitamin B6 was statistically significantly associated with lower risk of all cancers (relative risk [RR] = 0.78, 95% CI = 0.73 to 0.84) and specific tumors, with special regard to gastrointestinal carcinomas (RR = 0.68, 95% CI = 0.61 to 0.75). An inverse association was also observed between high PLP levels and the risk of all cancers (RR = 0.66, 95% CI = 0.58 to 0.76) and single tumor sites, the most consistent results being those for gastrointestinal tumors (RR = 0.56, 95% CI = 0.48 to 0.65). There was a statistically significant inverse linear relationship between cancer risk and both vitamin B6 dietary intake and PLP levels. When total (food and supplements) intake was considered, the associations were weaker or null. Findings from RCTs did not support a protective effect of vitamin B6 against cancer, although this evidence was graded as low level.
Epidemiological evidence supports the potential of vitamin B6 as a cancer risk reduction agent and the role of PLP as a cancer screening biomarker, especially for gastrointestinal tumors. However, inconsistent findings from total intake and intervention studies suggest that vitamin B6 might also be an indicator of other dietary protective micronutrients.
维生素 B6 参与多种生化反应,可能在致癌作用中发挥作用。我们总结了维生素 B6 与癌症风险之间关联的证据。
我们对观察性和干预性研究进行了系统综述,这些研究调查了维生素 B6 摄入或其生物活性形式吡哆醛-5'-磷酸(PLP)的血液水平与任何类型癌症风险之间的关系。采用随机效应荟萃分析计算了高摄入量与低摄入量类别之间的汇总相对风险(RR)及其 95%置信区间(CI)。我们还进行了随机效应剂量-反应荟萃分析。
我们确定了 121 项观察性研究(参与者 n=1924506;病例 n=96,436)和 9 项随机对照试验(RCTs;参与者 n=34911;病例 n=2539),共考虑了 19 个肿瘤部位。饮食(仅食物)中维生素 B6 高摄入量与所有癌症(RR=0.78,95%CI=0.73 至 0.84)和特定肿瘤的风险呈统计学显著负相关,特别关注胃肠道癌(RR=0.68,95%CI=0.61 至 0.75)。高 PLP 水平与所有癌症(RR=0.66,95%CI=0.58 至 0.76)和单个肿瘤部位的风险之间也存在负相关,结果最一致的是胃肠道肿瘤(RR=0.56,95%CI=0.48 至 0.65)。癌症风险与维生素 B6 饮食摄入量和 PLP 水平之间呈统计学显著的线性负相关。当考虑总摄入量(食物和补充剂)时,关联较弱或为零。RCT 的结果不支持维生素 B6 对癌症的保护作用,但这一证据被评为低水平。
流行病学证据支持维生素 B6 作为癌症风险降低剂的潜力,以及 PLP 作为癌症筛查生物标志物的作用,特别是对胃肠道肿瘤。然而,来自总摄入量和干预性研究的不一致发现表明,维生素 B6 也可能是其他膳食保护微量营养素的指标。